Potential of immunoglobulin A to prevent allergic asthma by Gloudemans, A.K. (Anouk) et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2013, Article ID 542091, 12 pages
http://dx.doi.org/10.1155/2013/542091
Review Article
Potential of Immunoglobulin A to Prevent Allergic Asthma
Anouk K. Gloudemans,1,2 Bart N. Lambrecht,1,3 and Hermelijn H. Smits2
1 Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands
2 Leiden Immunoparasitology Group, Department of Parasitology, Leiden University Medical Center, Albinusdreef 2,
P4-37A, 2333 ZA Leiden, The Netherlands
3 Laboratory of Immunoregulation and Mucosal Immunology, Department of Molecular Biomedical Research, VIB,
Technologiepark 927, 9052 Ghent, Belgium
Correspondence should be addressed to Hermelijn H. Smits; h.h.smits@lumc.nl
Received 31 January 2013; Revised 15 March 2013; Accepted 16 March 2013
Academic Editor: Mohamad Mohty
Copyright © 2013 Anouk K. Gloudemans et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Allergic asthma is characterized by bronchial hyperresponsiveness, a defective barrier function, and eosinophilic lower airway
inflammation in response to allergens. The inflammation is dominated by Th2 cells and IgE molecules and supplemented with
Th17 cells in severe asthma. In contrast, in healthy individuals, allergen-specific IgA and IgG4 molecules are found but no IgE, and
their T cells fail to proliferate in response to allergens, probably because of the development of regulatory processes that actively
suppress responses to allergens. The presence of allergen-specific secretory IgA has drawn little attention so far, although a few
epidemiological studies point at a reverse association between IgA levels and the incidence of allergic airway disease. This review
highlights the latest literature on the role of mucosal IgA in protection against allergic airway disease, the mechanisms described to
induce secretory IgA, and the role of (mucosal) dendritic cells in this process. Finally, we discuss how this information can be used
to translate into the development of new therapies for allergic diseases based on, or supplemented with, IgA boosting strategies.
1. Introduction
Allergic asthma is a major health problem worldwide, caus-
ing episodes of wheezing, coughing, and breathlessness in
susceptible individuals after repeated inhalation of harmless
environmental allergens, such as house-dust mites (HDMs),
molds, plant pollen, and animal dander [1, 2]. Currently
approximately 300 million people worldwide suffer from
asthma, with estimates suggesting that asthma prevalence
increases globally by 50% every decade. Prevalence has
reached a peak in developed countries, but rates are rising
in developing regions (Africa, Latin America, and parts of
Asia) as they becomemore westernized.This has reduced the
global differences in prevalence; however, the global burden
of asthma and allergies continues to rise, and new therapies
are warranted [3, 4].
Interestingly, negative associations are found between the
prevalence of allergic asthma and growing up on traditional
European farms or rural tropical areas, usually exposed to
higher ambient concentrations of microbial pollutants or
higher rates of parasitic infections [5, 6]. Therefore, it was
suggested that a reduced microbial exposure during child-
hood, due to changes in lifestyle, vaccination patterns, and/or
improved hygiene, has contributed to the global increases in
hyperinflammatory diseases. Insufficient microbial exposure
may result in deficient maturation of the regulatory arm of
the immune system, causing a disbalance of the immune sys-
tem, allowing for uncontrolled expression of inflammatory
responses against innocuous antigens later in life (“hygiene
hypothesis”) [7].
Currently used medication against asthma is aimed at
symptom relieve and does not restore this immune disbal-
ance. As a consequence, treatment is chronic and sometimes
resulting in severe side effects. New therapies should focus
on reducing inflammatory responses against allergens at
an early age preventing the onset of structural damage
and changes to the lungs, by targeting natural tolerizing
mechanisms as found in healthy individuals. In this review,
we will focus on one of these mechanisms and describe
the potential of inducing IgA responses by modulation of
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dendritic cell function and controlling unwanted allergic
responses.
2. Immune Responses against Allergens
2.1. Inflammatory Reactions against Inhaled Allergens in Aller-
gic Asthma: Th2 Cells and IgE. Allergic asthma is a chronic
inflammation of the airways controlled by effector Th2 cells
and characterized by eosinophilic airway inflammation and
high levels of allergen-specific IgE antibodies, hallmarks of
a persistent Th2 response [2] (Figure 3(a)). Upon encounter
with the allergen, effector responses can be divided into
immediate and late phase reactions. The immediate allergic
inflammatory reaction is initiated by crosslinking of IgE
molecules which are bound to IgE receptors on basophils and
mast cells. As a result, these cells will degranulate and release
preformedmediators from vesicles or secrete cytokines (IL-6,
TNF𝛼, MIP1𝛼) [9], causing immediate vascular permeabil-
ity, blood vessel dilation, bronchoconstriction, and smooth
muscle contraction [10]. This immediate reaction may be
followed by the late phase response, initiated by inflammatory
cytokines and type 2 cytokines, such as IL-4, IL-5, Il-9, and
IL-13, which recruit and activate eosinophils and basophils
and induce gobleT-Cell metaplasia and overproduction of
mucus [11, 12]. In severe forms of asthma, also Th17 cells
are found, which enhance the effects of the Th2 cytokines
and recruit neutrophils and other inflammatory leukocytes
[13–15]. In addition to distortion of immunological pathways
during allergen sensitization and challenge, also aberrant
structural airway remodeling is involved in the develop-
ment of asthma. Some groups have even suggested that
the airway structural changes occur before the deranged
immune response is present. Indeed, basement membrane
thickening is detectable in children younger than three years
old with persistent wheezing before the diagnosis of asthma
[16, 17]. Airway remodeling includes marked changes in
the airway wall, like epithelial injury, extracellular matrix
deposition under the epithelial basal membrane, gobleT-
Cell hyperplasia, and increased smooth muscle mass. These
changes lead to a defective physical and functional barrier
of the airway epithelium in severe asthma. Various studies
point at dysfunctional injury/repair mechanisms in response
to damaging stimuli and/or respiratory viruses in asthmatics,
which may only be in part explained by allergic airways
inflammation [18, 19].
Dendritic cells (DCs) play a crucial role in the described
processes leading to asthma pathogenesis (Figure 3(a)).
Immature DCs reside in peripheral and mucosal tissues,
such as the lungs, where they continuously sample the
environment for foreign soluble antigens and small par-
ticles, including inhaled allergens [20, 21]. DCs express
different types of pattern recognition receptors (PRRs), such
as toll-like receptors (TLRs), NOD-like receptors, and C-
type lectin receptors, that allow the recognition of different
classes of molecules broadly shared by pathogens (pathogen-
associated molecular patterns (PAMPs)) [22, 23]. Upon
encounter of danger signals, DCs become activated and
migrate to the draining lymph nodes [24], where they activate
antigen-specific na¨ıveTh cells and drive their development in
effector T helper cells, such asTh1,Th2,Th17, or regulatory T
(Treg) cells [25, 26]. Various studies have demonstrated that
DCs are necessary for inducing allergic sensitization [27], for
driving the development of Th2 immunity and eosinophilia
[28–30], and are crucial for maintaining the inflammatory
processes in the airways as well as bronchial hyperreactivity
and chronic airway remodeling [31, 32]. After allergen uptake,
the function of DCs is strongly influenced by signals encoun-
tered during their stay in the peripheral tissues, which can
include microbial signals induced by the ligation of pattern
recognition receptors (PRRs) on the DCs or alarming signals
from structural cells like local epithelial cells of the airways
[33–35]. Crosstalk between airway epithelial cells and DCs
may form a critical link for the induction and continuation
of allergic inflammation in the lungs as several EC-derived
molecules can influence DC migration, differentiation, and
function [20, 33, 36].
2.2. “Tolerizing” Immune Responses to Allergens in Healthy
Individuals: Treg Cells and IgA. In healthy individuals, T-cell
responses to allergens are commonly observed, yet are usually
dominated by anergy or by regulatory T (Treg) cells that can
suppress various effector Th cell subsets [37, 38]. Allergen-
specific Treg cells can suppress Th2 cells by cell-cell contact
or release of the anti-inflammatory and immunoregulatory
cytokines IL-10 and transforming growth factor (TGF)-
𝛽. In almost all patients with asthma, one can find the
counterregulatory Treg cells, but these fail to or insufficiently
suppress allergic inflammation [39]. It has therefore been
suggested that asthma may result from aberrant of defective
Treg mechanisms.
Humoral responses of healthy individuals consist of
mainly low IgG1, IgG4, and secretory IgA (sIgA) antibodies to
allergens in the presence or absence of low amounts of IgE [37,
40, 41]. Although the presence of allergen-specific IgA has
drawn relatively little attention so far, it is still unclear what its
relative role is in the protection (or exacerbation) of allergic
disease [42]. Although most individuals with immunoglob-
ulin A (IgA) deficiency are asymptomatic, allergic disorders
appear to be more common among patients with IgA defi-
ciency [43]. Indeed, Balzar et al. found lower IgA levels in
bronchoalveolar lavage of severe asthmatics than in healthy
subjects, which correlated with lung function and asthma
symptoms [44]. In contrast, high salivary secretory IgA levels
were associated with less development of allergic symptoms
in sensitized Swedish children [45]. Furthermore, high levels
of specific IgA antibodies in salivary of sensitized infants were
associated with significantly less late-onset wheezing [46]. In
addition, allergic patients who naturally develop tolerance
responses towards cow’s milk concomitantly undergo a shift
towards IgA dominance in serum [47]. Moreover, in an
experimental setting, Schwarze was able to protect mice
against the development of eosinophilic airway inflammation
and hyperresponsiveness by treating with antigen-specific
IgA during challenge [48].
Taken together, these data show an inverse relationship
between IgA and allergy development, suggesting a protective
role for IgA in allergic diseases such as asthma.
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Figure 1: Human IgA structure. Schematic diagrams of (a) IgA subclass 1 (IgA1), (b) IgA2, (c) dimeric IgA1 (dIgA1), (d) secretory IgA1, and
(e) polymeric immunoglobulin receptor (pIgR) (adapted from [8]).
3. Immunoglobulin A Antibodies and
Its Functions
3.1. Isoforms and Receptors. The antibody IgA can occur as
a monomer (Figures 1(a) and 1(b)), but also in dimeric or
even polymeric forms through interactions with the joining
chain (J-chain) (Figure 1(c)). All these different forms are
mainly found in the circulation, while secretory IgA (sIgA)
is only found at mucosal surfaces and is generated by the
binding of dimeric IgA via the J-chain to the polymeric
immunoglobulin receptor (pIgR) at the basolateral side of the
epithelium which is subsequently transported to the luminal
side (Figures 1(d) and 1(e)). Here, IgA is released at the
mucosal surface (lumen) by cleavage from the pIgR. In this
process part of the pIgR, called the secretory component (SC),
remains attached to the IgAmolecule, and together they form
the molecule secretory IgA (SIgA). Mouse and human IgA
biology differ in several aspects. In human serum, IgA occurs
mainly in a monomeric form, while in mice polymeric IgA is
the main isotype in serum. Furthermore, human IgA, but not
mouse IgA, is divided into closely related subclasses, IgA1 and
IgA2, of which the later one is less susceptible for proteolytic
degradation (Figures 1(a) and 1(b)). In serum, the subclass
IgA1 is dominant, while in secretions themain isoform found
is IgA2, although both IgA1 and IgA2 can be detected as SIgA
[49].
IgA has been described to interact with various host
receptors, that is, pIgR, Fc𝛼RI (CD89), transferrin receptor
(CD71), asialoglycoprotein receptor (ASGPR), and Fc𝛼/𝜇R.
The consequences after ligation are not very clear for most of
these receptors. However, the Fc𝛼RI allows both inhibitory
and activating signals and therefore is considered to be
important for the role of IgA in preserving homeostasis and
tolerance at mucosal sites [8, 50]. Moreover, Fc𝛼RI is the
only IgA Fc receptor expressed on (blood) myeloid cells,
including DCs, monocytes/macrophages, neutrophils, and
eosinophils. In mucosal areas in steady state conditions, only
few cells are positive for Fc𝛼RI. Intriguingly, this receptor
has not been identified in mice. Although this receptor is
associated with an immunoreceptor tyrosine-based activa-
tion motifs (ITAM), its signaling can be activating as well
as inhibitory. This depends on the ligand and subsequent
configuration (involving Syk or SHP-1 phosphatase) of the
ITAM, resulting in an activating or an inhibitory ITAMmotif.
The inhibitory ITAM (ITAMi) pathway takes place in the
absence of receptor coaggregation and of an immunoreceptor
tyrosine-based inhibitory motif (ITIM), which is known
for inhibiting immune responses. All forms of IgA can
ligate to Fc𝛼RI, but they differ in their binding capacities.
Monomeric IgA only binds with low affinity to the Fc𝛼RI and
activates the ITAMi, which does not lead to cell activation or
degranulation/oxidative burst (in the case of granulocytes)
[51]. In contrast, IgA complexes show a stronger binding
and subsequent activating signal, resulting in cell activation
[52, 53].
3.2. Effector Functions of IgA. IgA is classically known for
neutralizing toxins and bacteria (viruses) at mucosal surfaces
[54, 55], by interfering with their motility, by competing for
epithelial adhesion sites, and by improving the viscoelastic
properties of the airway secretions [56].The SC protects SIgA
from proteolytic degradation and is involved in establishing
local interactionswith bronchialmucus, thereby contributing
to the “trapping” and removal of the antigen (“immune
exclusion”) [57]. Interestingly, it has been suggested that IgA
can also directly reduce inflammatory responses by inhibiting
effector functions of inflammatory cells. For example, anti-
Fc𝛼RI Fab treatment, by initiating ITAMi signaling, sup-
pressedmanifestations of allergic asthma in Fc𝛼RI transgenic
mice immunized with anti-IgE immune complexes [58].
Triggering ITAMi signaling also prevented marked inflam-
mation and leukocyte infiltration in kidney inflammation
models such as glomerulonephritis [59]. Furthermore, in
vitro crosslinking of Fc𝛼RI on humanmonocyte-derivedDCs
leads to internalization of IgA complexes and antigen pre-
sentation, resulting in DC maturation and IL-10 production
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[60, 61]. (Serum) IgA ligation on monocytes also induces IL-
10 expression [62] and inhibits inflammatory cytokine (IL-6
and TNF𝛼) release [63, 64]. Importantly, IgA has only limited
capacity to activate the complement system, in contrast to
IgG and IgM. Furthermore, it can competitively block the
IgG-mediated activation of complement [8, 65]. Of note,
a few specific diseases are associated with an increase in
serum IgA levels, often paralleled by IgA tissue deposition
[66]. In IgA nephropathy, the formation of aggregated IgA
immune complexes in the kidney causes severe inflammatory
responses [67, 68]. However, there are indications that in
these patients, glycosylation (e.g., sialylation) of the circu-
lating IgA antibodies is abnormal, which may explain the
pathogenic potential [53].
Collectively, these data suggest that under homeostatic
conditions, secretory IgA contributes to the maintenance of
mucosal tolerance by dampening immune responses. There-
fore, IgA can have a role in preventing the development of
hyperinflammatory responses towards environmental aller-
gens that otherwise could cause allergic inflammation as
observed in allergic rhinitis or asthma.
4. Regulation of Immunoglobulin A Responses
4.1. T-Cell-Dependent and T-Cell-Independent IgA Class
Switching. Humoral responses in the mouse are mediated
by at least three different subpopulations of mature B cells.
These B cells can acquire the expression of various antibody
isotypes, including IgA, by undergoing class switch recombi-
nation (CSR). In contrast to other isotypes, IgA class switch-
ing can occur both via a conventional T-Cell-dependent
(TD) pathway and an alternative T-cell-independent (TI)
pathway (Figure 2). Follicular (or B-2) B cells, located in the
spleen, lymph nodes, and the Peyer’s Patches respond to T-
cell-dependent antigens and can acquire the expression of
various isotypes by undergoing class switch recombination
(CSR).The resulting IgA+-B cells will migrate to the draining
effector sites. TD class switch is induced by CD40-CD40L
ligation and specific cytokines secreted by T cells as a result of
activation by DCs or other APCs. The major cytokine signal
for 𝛼-CSR is TGF-𝛽 with contributions from IL-2, IL-4, IL-5,
IL-6, IL-10, and IL-21 [69–72] (Figure 2 TD pathway).
Nonfollicular B cells, such as the splenic marginal zone
B cells and the B-1 cells, which are mostly enriched in
the peritoneal and pleural cavity and the lamina propria
of the small and large intestines, primarily respond to T-
cell-independent antigens and secrete natural or polyspecific
antibodies [73]. The alternative TI pathway occurs locally at
effector sites and is a much faster mechanism to generate IgA.
TI class switching is induced independently of CD40-CD40L
engagement and needs alternative costimulatory signals, such
as B-cell activating factor of the TNF family (BAFF, also
known as BLyS), a proliferation-inducing ligand (APRIL),
retinoic acid (RA), TGF-𝛽, nitric oxide (NO), and/or IL-6.
These IgA costimulatory factors can be produced by both
resident epithelial cells of mucosal organs and by local DCs.
In fact, mucosal DCs, from Peyer’s Patches (PPs), gut lamina
propria [74], or lungs [75], are the primary APCs able to drive
TI IgA class switching. Once CSR has taken place, most of
these factors, including BAFF and APRIL, further enhance
both TD and TI IgA responses by providing survival signals,
and/or inducing plasma cell differentiation and IgA secretion,
pointing at an additional role of structural cells and DCs at a
later stage of IgA development [69–71] (Figure 2 TI pathway).
It is increasingly clear that gut IgA-producing B cells can
be both generated from follicular B cells or the B-1 cells
by complementary pathways, requiring different signals to
undergo IgA switching which links back to their capacity
to respond to TD or TI antigens. For example, peritoneal
B-1 cells more readily switch to IgA in vitro in response to
BAFF, TLR ligation, and TGF-𝛽, while follicular B cells or
peritoneal B-2 cells require cytokines like IL-4, IL-5, or anti-
IgD dextran [76]. Interestingly, B-1 cells can switch to all
immunoglobulins in vitro, while in vivo studies with SCID
mice or irradiated mice reconstituted with bone marrow or
peritoneal cavity cells have suggested that B-1 cells preferen-
tially switch to IgA [77, 78], where they accounted for most
of the gut IgA plasma cells. However, studies in gnotobiotic
allotype Ig chimeric mice (allowing the distinction between
Abs derived fromB1 and B2 cells based on different allotypes)
suggested that in normal immunocompetent mice intestinal
B-2 cells contributed for most of the IgA found in the gut
in response to gut bacteria [79]. Importantly, also in the
respiratory tract and their draining lymph nodes local B-1
cells have been demonstrated [80]; however, the respective
role of B-1 or follicular B cells in the production of IgA has
not been studied yet. The relative role of B-1 versus B-2 cells
in IgA-mediated immunity is reviewed elsewhere [72].
Theoretically, it might be possible to induce in situCSR of
existing allergen-specific IgE+ B cells into IgA
2
+ cells. Because
CH𝛼2 is the last exon located downstream from CH𝜀 in the
human heavy chain locus, this may be the only alternative for
CSR in IgE+ B cells. Shifting the allergen-specific antibody
response from IgE to IgA2 would result in neutralization
of allergen in the mucosal lumen, before it could interact
with IgE, and could therefore constitute a therapeutic target.
Although this has not been tested nor reported yet, based on
the role of IL-21 and TGF-𝛽 in IgA class switching [81], they
may contribute to induce IgA2 production in already class-
switched B cells.
4.2. Role of Mucosal Dendritic Cells and TLRs. Mucosal con-
ditioning of DCs occurs via resident tissue-derived factors,
such as thymic stromal lymphopoietin (TSLP), IFN-𝛽, RA,
and TGF-𝛽, but also by ligation of toll-like receptor (TLR) lig-
ands expressed by (commensal) bacteria [82–84] (Figure 2).
Epithelial cells release these DC conditioning factors in
addition to other IgA stimulatory factors in response to TLR
ligands [85]. In the gut lamina propria, several specialized
DC subsets are described with an enhanced intrinsic capacity
to drive IgA CSR. For example, Tip DCs express inducible
nitric oxide synthase (iNOS) in response to TLR signaling
and initiate TI IgA production by releasing BAFF and APRIL
[86]. CD11chiCD11bhi DCs induce TI IgA production upon
sensing bacteria through TLR5, a process that elicits release
of RA and IL-6 [87]. CD103+ DCs are known for driving
the differentiation of FoxP3+ Treg cells. As the main RA
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producing subset, they are also responsible for imprinting
gut-homing molecules on B cells and support IgA synthesis
[74]. How these DCs acquire their tolerogenic properties is
not yet fully understood, but a role for microbial activation
was suggested [88, 89]. Recently, it was published that in vitro
mouse CD11bhi lung DCs induce IgA more efficiently than
CD103+ lung DCs [90]. The use of CD11b as a marker for
lungDCs is however confusing, as CD11b is not only found on
a subset of conventional (c)DCs, but also on the population
of monocyte-derived DCs (moDCs) that are recruited to the
lungs at times of inflammation [91].
In addition to the conventional mouse DC subsets which
drive IgA synthesis and are portrayed in the previous para-
graph, also a plasmacytoid (p)DC subset has been described
[92]. These pDCs differ from cDCs in expressing lower
amounts of CD11c, yet they produce very high amounts of
IFN𝛼. Although both mouse gut lymph node-derived pDCs
and cDCs were able to support B-cell IgA production, pDCs
were more superior in vitro due to type 1 IFN dependent
enhanced APRIL and BAFF expression [93]. Also in humans,
IFN𝛼 producing pDCs seem to be more advanced in sup-
porting B-cell proliferation and differentiation into antibody
producing cells, including IgA, compared to myeloid DCs
(mDC, grossly equivalent to mouse cDC subset) [94, 95].
Altogether DCs form a crucial cell type in the differen-
tiation of IgA responses. Although by different mechanisms,
both cDCs and pDCs can promote Ig responses, and their IgA
inducing capacity can be enhanced by local factors produced
by mucosal tissues as well as by (local) microbial products
such as TLR ligands.
4.3. Early Priming and the Microbiota. The establishment
of commensal flora in the intestine, and most likely also
the respiratory tract [96], starts at birth and is considered
to be crucial for stimulating and directing the develop-
ment of the host immune system. Animals raised under
germ-free conditions have an undeveloped immune system
with fewer germinal centers and decreased number of IgA-
producing plasma cells [97]. Interestingly, gut microbiota is
necessary for a protective immune system, includingmucosal
IgA responses, in the airways. In response to OVA, germ-
free (GF) mice developed more severe features of airway
inflammation compared to control specific pathogen free
(SPF) mice, which could be reversed by recolonization of
GF mice with complex commensal flora. Furthermore, the
absence of commensal bacteria was associated with less
pDCs and attenuated production of IgA in the airways
[98]. Human studies have also suggested the link between
commensals and allergy. Indeed, children who developed
allergy had significantly less diverse gutmicrobiota and lower
levels of salivary SIgA [99], while, intestinal colonization by
Staphylococcus aureus was associated with high circulating
IgA levels and with a lower frequency of eczema [100]. The
exact number and diversity of an individual’s community of
commensals seem to be determined by factors occurring in
early childhood [101]. Several mouse and human studies have
shown that early life (prenatal, preconception) exposure to
environments characterized by a diverse and concentrated
microbialmilieu such as traditional farming sitesmay protect
against the development of allergic diseases [102–105]. Breast
milk contains many Igs and may have a collective tolerogenic
effect acting via sIgA, cytokines, and/or immune complexes
[106].
A rich microbial environment contributes to mucosal
tolerance and protective IgA responses, which are associated
with protection against allergic asthma. The ideal candidate
for an adjuvant stimulating protective IgA responses and
thereby preventing development of allergic asthma could
therefore be a microbial-derived molecule.
5. Strategy for Allergy Intervention via
Induction of IgA
5.1. Cholera Toxin B, an IgA InducingAdjuvant. Cholera toxin
is the most widely experimentally used mucosal adjuvant,
potentiating serum and local immune responses to coad-
ministered antigens [107]. The enterotoxin Cholera Toxin is
produced by the bacterium Vibrio cholerae and consists of
an A and B subunit, each with distinct effects on cells of
the immune system. The A subunit is known for its toxic
(side) effects: after entering the cell cytosol, the A subunit
triggers electrolyte efflux via activation of adenylate cyclase
and increased cyclic AMP (cAMP) production, resulting
in severe watery diarrhea. The B subunit of CT (CTB) is
more considered as a nontoxic subunit, as it is not linked
to the activation of cAMP and its adjuvant activity seems
to be mainly associated with immunoregulatory events [107,
108]. For example, feeding of CTB conjugated to myelin
basic protein before or after disease induction protected rats
from experimental autoimmune encephalomyelitis [109], and
nasal administration of CTB insulin significantly delayed
incidence of spontaneous diabetes in NOD mice [110]. In
these models, protection against autoimmunity by CTB/Ag
conjugates was associated with the formation of Treg cells
expressing IL-10 and/or TGF-𝛽 [109]. The tolerizing effect
of CTB has also been shown to extend to other immune-
mediated diseases. In a delayed type hypersensitivity model,
(prolonged) oral treatmentwith lowdoses ofOVAconjugated
to CTB prevented sensitization and suppressed IgE antibody
responses in sensitized mice [111]. Furthermore, intranasal
pretreatment of CTB linked to the BetV1, a major allergen
of birch pollen, prevented sensitization to the antigen by
shifting the Th2 response towards Th1 and the induction of
allergen-specific IgA responses [112]. Likewise, we found that
CTB administration in the lungs stimulates local secretory
IgA responses which protected against the development of
allergic airway inflammation (AAI), while mice deficient for
polymeric Ig receptor (pIgR) and lacking SIgA were not [113].
Interestingly, the primary action of CTB as an adjuvant may
be primarily mediated through a direct effect on APCs such
as DCs. Upon in vivo administration, CTB mainly effected
cDCs and not so much pDCs, while adoptive transfer of in
vitro generated CTB treated DCs was sufficient to enhance
IgA responses in mouse lungs [113]. Furthermore, in vitro
cocultures of CTB exposed bone marrow-derived DCs and B
cells also resulted in the induction of IgA production. These
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in vitro experiments suggest that asynergism between CTB
and MyD88-dependent TLR signals selectively imprints an
IgA inducing phenotype in DCs, characterized by RALDH1
and TGF-𝛽 expression [114]. Upon exposure to CTB in vivo,
ALDH activity was mainly enhanced in the CD11b+ DCs,
which may include mo-DCs (Figure 3(b)). Also the experi-
ments with the bone marrow-derived DCs differentiated in
GM-CSF, which are a good model for these inflammatory
DCs,may suggest that (CD11b+)moDCs could be responsible
for CTB induced IgA responses in the mouse airways. This is
certainly a possibility as CTB seems to work best at inducing
IgA responses when accompanied by some degree of LPS.
LPS is a known trigger of moDC recruitment [115]. Until we
have more specific depleting antibodies or transgenic mouse
strains to selectively deplete moDCs, we can however only
speculate at this stage whether this is true.
If we are to exploit the full potential of IgA as an
immunomodulatory immunoglobulin in allergic asthma and
other immune mediated diseases, the role of different DC
subsets in the regulation of humoral IgA responses and
modulation by adjuvants should be studied in more detail.
5.2. Allergen-Specific Immunotherapy. Allergen-specific im-
munotherapy (SIT) represents the only curative treatment of
allergic diseases currently available and involves the incre-
mental delivery of the allergen to which the individual is
sensitive [116]. Successful IT components of the regulatory
network such as Treg cells and the cytokine IL-10 are
elevated, while allergen-specific IgE levels are reduced. It is
hypothesized that the enhanced immunoregulatory network
is instrumental in suppressing allergen-specific effector T
cells which are responsible for many of the characteristics
of allergic diseases. IL-10 does not only contribute to T-Cell
tolerance but also potently suppresses total and allergen-
specific IgE, and it simultaneously increases IgG4 and IgA
production in cultures [117, 118]. Interestingly, successful
immunotherapy is also associated with increases in IgA
responses in vivo. In a 2-year double blind trial, grass-
pollen immunotherapy induced a shift in allergen-specific
antibody response towards IgA2, which correlated with
increased local TGF-𝛽 expression and induced monocyte IL-
10 expression [119]. Another study using sublingual grass-
pollen immunotherapy (SLIT) reported increases in allergen-
specific IgG4 and IgA [120].
In its current form, SIT has major drawbacks and
cannot compete with treatment on the basis of symptom
relief (antihistamines and corticosteroids) for many asthma
patients. High concentrations of allergen extract need to be
administered on a long term (∼5 years) and regular basis.
This introduces a risk of potentially life-threatening allergic
reactions [121]. Therefore, it might be interesting to apply
the use of tolerogenic adjuvants, specifically inducing Treg
cells and/or secretory IgA to improve efficacy and safety
of SIT. For example, when the allergen is coupled to the
adjuvant CTB, it will be efficiently targeted to the DC [113],
allowing the use of lower allergen doses and decreasing the
risk of anaphylactic shocks. Future experiments in mouse
models for true allergens, like birch pollen or house-dust
mite, experimental SIT models, and (cells from) allergic
patients will need to point out the usefulness of application
of the class of “mucosal” adjuvants in current SIT protocols.
5.3. Boosting IgA as a Preventive Strategy. The establishment
of commensal flora in the intestine and respiratory tract
starts at birth and is considered to be crucial for stimu-
lating and directing the development of the host immune
system, including the mucosal IgA response [97, 122, 123].
In our in vitro coculture system, we confirmed the role
for microbial-derived TLR ligands in the conditioning of
DCs for stimulating IgA responses. Interestingly, themucosal
adjuvant CTB does not only enhance IgA induction by
TLR-ligand primed DCs, but also initiates IgA production
in the case of low dose exposure to MyD88-activating
signals which are insufficient to induce IgA on their own
[114]. This is interesting considering the hypothesis that
decreased or altered microbial exposure associated with an
affluent life style is contributing to the increase in asthma
prevalence during the last decades. Only recently we have
started to appreciate the importance of the microbiota on
human health, and restoring or manipulating disrupted host-
microbiota relationship has become a potent strategy for
treating inflammatory diseases, including asthma [124]. CTB
could contribute to broad antibody repertoire and sufficient
mucosal IgA levels in people with impaired or delayed IgA
synthesis, by reducing the threshold for microbial signals
or providing the necessary cosignals, to maintain mucosal
immunity and local homeostasis (Figure 3).
It was shown that children who developed allergy had
less diverse (gut and airway) microbiota [99] and decreased
serum or mucosal IgA responses [45, 46, 100] compared to
healthy controls. Studies that measured IgA levels at different
time points showed an increase over time which may be
due to microbial exposure and microbiota development [45,
100]. Especially during the first months and year, events
such as mode of birth delivery, type of “first” milk (breast
versus formula milk), and microbial exposure will determine
the composition of microbiota [122]. This suggests that
particularly during this early period in life impaired IgA
responses may allow for sensitization and/or development of
allergic symptoms. By the time that allergic (asthma) patients
have reached adulthood, impaired IgA responses may be
restored to normal levels, but the “damage” has already
occurred and allergen-specific inflammatory responses have
developed. Indeed, in a cohort of adult allergic asthmatic
patients, we did not find reduced (secretory) IgA levels in
nasal washes compared to nonallergic controls (Gloudemans
et al., unpublished observations). Alternatively, in a fraction
of the allergic infants with a slowly developing mucosal IgA
repertoire, allergy symptoms may relieve together with the
establishment of a fully developed IgA response. Thus, one
should keep in mind that the association between IgA and
asthma may be misinterpreted using an adult cohort.
6. Words of Caution
The effector function of IgA is very much depending on
local (inflammatory) factors present and needs to be care-
fully examined before applying IgA enhancing therapy. For
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example, IgA immune complexes bind with stronger affinity,
subsequently resulting in cell activation and elimination
of the pathogen [52, 53]. In certain cases, IgA complexes
can even cause severe inflammation and pathology, like in
immune complex glomerulonephritis [68, 125]. Importantly,
eosinophils andneutrophils express receptors for IgA that can
activate the cells upon binding of IgA immune complexes
[51, 126], resulting in activation and/or degranulation of
the cell [50, 127]. Therefore, also in severe asthma, where
in addition to eosinophils also neutrophils are important
mediators, IgA may aggravate the inflammation instead of
promoting tolerance. Interestingly, both in patients with
IgA nephropathy and in patients with asthma, abnormal
glycosylation of the IgA antibody or the Fc𝛼RI receptor was
found, which may allow exacerbated immune responses and
disease development instead [128, 129].
In addition to the isoform of IgA and local tissue factors,
reactivity or specificity of the antibody will determine the
receptor binding affinity and thus the immunological effect
of Ig-receptor ligation. Primitive or polyreactive (natural)
IgA antibodies are sufficient to protect the host from excess
mucosal immune stimulation by harmless commensal bac-
teria and may protect against some noninvasive parasites
[130, 131]. However, affinity maturation of IgA is necessary to
provide protection from more invasive commensal bacteria
and from true pathogens. Thus, there seems to be a corre-
lation between the “sophistication” of the IgA response and
the aggressiveness of the subsequent immune response, at
least in the gut [132]. However, it still remains unclear how
this applies for environmental particles in the lung, such as
inhaled allergens. Therefore, to evaluate the efficacy of IgA-
based treatment against allergic diseases, not only the level of
mucosal IgA responses need to be carefully studied in health
and disease, but also aspects such as the affinity and reactivity
of the antibodies should be taken into account.
Although local IgA induction during specific immun-
otherapy may have potential to improve the treatment of
allergic airway inflammation, based on the dynamics of the
development of IgA responses in life and the functional
duality of the IgA-receptor interaction, it seems essential to
stimulate IgA responses under noninflammatory conditions.
Therefore, we hypothesize that the development of protec-
tive mucosal IgA responses will occur best in the context
of a homeostatic environment, through the activation of
dedicated mDCs and/or mo-DCs, aiming at the induction
of a fully developed mucosal IgA repertoire in time and
preventing the development of inflammatory responses to
allergens (Figure 3).
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